Van ECK Associates Corp Buys 6,973 Shares of Becton, Dickinson and Company $BDX

Van ECK Associates Corp boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 23.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,144 shares of the medical instruments supplier’s stock after acquiring an additional 6,973 shares during the period. Van ECK Associates Corp’s holdings in Becton, Dickinson and Company were worth $5,621,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. lifted its holdings in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the period. Main Street Group LTD bought a new stake in Becton, Dickinson and Company during the first quarter valued at $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $187.58 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The business’s fifty day moving average is $168.75 and its 200 day moving average is $160.44. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $51.69 billion, a P/E ratio of 56.50, a P/E/G ratio of 13.19 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the business posted $3.68 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BDX shares. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Royal Bank Of Canada increased their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $187.67.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 9,105 shares of company stock valued at $1,590,208. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.